IBC has taken the lead to bring all the industry experts together to give you the answers you need to move ahead your discovery, design or development program.
IBC's Next Generation Protein Therapeutics Summit is the only conference on the market which consistently brings together every leading company and academic scientist working in alternative scaffold and next-generation protein therapeutic development.
Merck Serono announced a collaboration for promotion of the type 2 diabetes drug Glucophage under different formulations in China. The collaboration will seek to expand the geographic distribution of Glucophage as well as provide diabetes-related health and medical information.
Scientists have discovered that pancreatic cancer cells' growth and spread are fueled by an unusual metabolic pathway that someday might be blocked with targeted drugs. Cancer cells are known to "wire" their metabolic circuits differently from normal cells to provide energy for cancerous growth.
Cancer Research Technology and The Institute of Cancer Research are collaborating with Janssen Biotech Inc. to discover a potential new multiple myeloma drug. Multiple myeloma is often effectively treated initially, but many patients become resistant to treatment, and there is an urgent need for new therapies.
The Food and Drug Administration announced that it has approved Tecfidera to control multiple sclerosis, or MS, in adults with hard-to-treat forms of the disease, a debilitating illness in which the body attacks its own nervous system. There is no cure for multiple sclerosis.
Trovagene Inc. has launched a urine-based test for a common, sexually transmitted virus that can cause cervical cancer, some other cancer types, and genital warts. HPV lurks in an estimated 79 million American women and men, most of whom don't know it.
Pozen Inc. announced the submission of a new drug application to the U.S. Food and Drug Administration for the marketing approval of two potential cardiovascular drugs. Posen's PA32540 and PA8140 are both intended as alternatives to plain aspirin for the prevention of cardiovascular disease.
Researchers have discovered that the antidiabetic drug metformin reduces the production of inflammatory cytokines that normally activate the immune system, but if overproduced can lead to pathological inflammation, a condition that both damages tissues in aging and favors tumor growth.
Ganetespib, a drug that indirectly impairs the function of several cancer-driving proteins, including anaplastic lymphoma kinase, may be an effective new treatment for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer.
Merck announced that the Biologics License Application for its investigational Timothy grass pollen allergy immunotherapy tablet has been accepted for review by the U.S. Food and Drug Administration. Merck previously submitted a BLA to the FDA for its investigational ragweed pollen AIT.
GlaxoSmithKline and Texas A&M announced that the U.S. Department of Health and Human Services has approved the establishment of a $91 million influenza-vaccines manufacturing facility as the anchor of the Center for Innovation in Advanced Development and Manufacturing in Bryan-College Station, Texas.
Two children with an aggressive form of childhood leukemia had a complete remission of their disease—showing no evidence of cancer cells in their bodies—after treatment with a novel cell therapy that reprogrammed their immune cells to rapidly multiply and destroy leukemia cells.
A research group has succeeded in rejuvenating the blood of mice by reversing, or re-programming, the stem cells that produce blood. These findings indicate that it may not primarily be damage to DNA that causes blood to age, but rather reversible epigenetic changes.
New research findings may help scientists design drugs to treat a virus infection that causes potentially fatal brain swelling and paralysis in children. The virus, called enterovirus 71, causes hand, foot and mouth disease and is common throughout the world.